Latin America Diabetes Drugs Market - Growth, Trends and Forecast (2019 - 2024)

The Latin America Diabetes Drugs Market is Segmented by Drug (insulin, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), and by Geography.

Market Snapshot

Picture 1
Study Period:

2012-2024

Base Year:

2018

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

  • The Latin American diabetes drugs market registered a value of USD 3.5 billion in 2017, and is expected to witness an approximate CAGR of 5% during the forecast period, primarily due to the growing geriatric population. 
  • The diabetic prevalence is high in the countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing type 2 population in the country. 
  • The gradually growing obesity rate combined with the genetic predisposition for type 2 diabetes is acting as a prominent driver for the increase in type 2 diabetic population over the last 40 years. 
  • Currently, close to 10% of the total population are living with diabetes in one form or the other. The diabetic patients in the Latin American region are mainly type 2 diabetic patients that account for close to 90% of the total diabetic population in 2017.  

Scope of the Report

The market studied is segmented by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), and by geography.

By Product Type Insulin Basal or Long Acting Insulins Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-Acting Insulins NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins Insulin Glargine Biosimilars
Human Insulin Biosimilars
Oral anti-diabetic drugs Biguanides Metformin
Alpha-Glucosidase Inhibitors Alpha-Glucosidase Inhibitors
SGLT2 inhibitors  Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP4 inhibitors Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas Sulfonylureas
Meglitinides Meglitinides
Non-Insulin Injectable drugs GLP1 receptor agonists Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Combination Drugs Insulin Combinations NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination Janumet (Sitagliptin and Metformin HCl)
By Geography Latin America Brazil
Mexico
Rest of Latin America
 

Key Market Trends

Oral Diabetic Drug has High Sales

  • Type 2 oral diabetic drug has high sales in this region mainly due to the low-cost factor.
  • Most of the drugs are generic and are priced in such a way that its lower than branded drugs.
  • Biguanides are considered to be the first class of oral drugs for type 2 patients.
  • Mexico is among the top 10 countries that have the highest market value and volume for Biguanides.
  • The market for the generic diabetic drug has a high potential for future growth in various countries in the LATAM region.
Picture3

To understand key trends, Download Sample Report

Brazil accounts for the highest market share in Latin Ameria diabetes drugs market

  • Brazil accounts for 51% of the diabetic drug market in LATAM. In 2017, mainly due to higher consumption of insulin by type 1 patients.
  • Brazil accounts for close to 78% of all the type 1 patients in the region. Basal insulin Lantus accounts for the largest share by value of 89% in 2017 in the Brazil insulin market.
Picture4

To understand geography trends, Download Sample Report

Competitive Landscape

  • Novo Nordisk holds the highest market share in the Latin America diabetes drug market.
  • Branded drugs of Eli Lilly & Boehringer Ingelheim Alliance is expected grow with the high CAGR of more than 15% in the forecast period

Major Players

  1. Novo Nordisk
  2. Sanofi
  3. Eli Lilly
  4. AstraZeneca

* Complete list of players covered available in the table of contents below

Picture5

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Oral Anti-diabetic Drugs

        1. 5.1.1.1 Biguanide (Value and Volume 2012-2024)

          1. 5.1.1.1.1 Metformin

        2. 5.1.1.2 Alpha - Glucosidase Inhibitors (Value and Volume 2012-2024)

          1. 5.1.1.2.1 Alpha - Glucosidase inhibitors

        3. 5.1.1.3 Sodium - glucose cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2024)

          1. 5.1.1.3.1 Invokana (Canagliflozin)

          2. 5.1.1.3.2 Jardiance (Empagliflozin)

          3. 5.1.1.3.3 Farxiga/Forxiga (Dapagliflozin)

          4. 5.1.1.3.4 Suglat (Ipragliflozin)

        4. 5.1.1.4 Dipeptidyl peptidase - 4 (DPP-4) inhibitors (Value and Volume 2012-2024)

          1. 5.1.1.4.1 Januvia (Sitagliptin)

          2. 5.1.1.4.2 Onglyza (Saxagliptin)

          3. 5.1.1.4.3 Tradjenta (Linagliptin)

          4. 5.1.1.4.4 Vipidia/Nesina (Alogliptin)

          5. 5.1.1.4.5 Galvus (Vildagliptin)

        5. 5.1.1.5 Sulfonylureas (Value and Volume 2012-2024)

          1. 5.1.1.5.1 Sulfonylureas

        6. 5.1.1.6 Meglitinide (Value and Volume 2012-2024)

          1. 5.1.1.6.1 Meglitinide

      2. 5.1.2 Insulin

        1. 5.1.2.1 Basal or Long Acting Insulins

          1. 5.1.2.1.1 Lantus (Insulin Glargine)

          2. 5.1.2.1.2 Levemir (Insulin Detemir)

          3. 5.1.2.1.3 Toujeo (Insulin Glargine)

          4. 5.1.2.1.4 Tresiba (Insulin Degludec)

          5. 5.1.2.1.5 Basaglar (Insulin Glargine)

        2. 5.1.2.2 Bolus or Fast Acting Insulins

          1. 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 5.1.2.2.2 Humalog (Insulin Lispro)

          3. 5.1.2.2.3 Apidra (Insulin Glulisine)

        3. 5.1.2.3 Traditional Human Insulins

          1. 5.1.2.3.1 Novolin/Actrapid/Insulatard

          2. 5.1.2.3.2 Humilin

          3. 5.1.2.3.3 Insuman

        4. 5.1.2.4 Biosimilar Insulins

          1. 5.1.2.4.1 Insulin Glargine Biosimilars

          2. 5.1.2.4.2 Human Insulin Biosimilars

      3. 5.1.3 Non-Insulin Injectable drugs

        1. 5.1.3.1 GLP1 receptor agonists

          1. 5.1.3.1.1 Victoza (Liraglutide)

          2. 5.1.3.1.2 Byetta (Exenatide)

          3. 5.1.3.1.3 Bydureon (Exenatide)

          4. 5.1.3.1.4 Trulicity (Dulaglutide)

          5. 5.1.3.1.5 Lyxumia (Lixisenatide)

      4. 5.1.4 Combination Drugs

        1. 5.1.4.1 Insulin Combinations

          1. 5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)

          2. 5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

        2. 5.1.4.2 Oral Combination

          1. 5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)

    2. 5.2 Geography

      1. 5.2.1 Latin America

        1. 5.2.1.1 Brazil (Value and Volume 2012-2024)

          1. 5.2.1.1.1 Oral Anti-diabetic Drugs

          2. 5.2.1.1.2 Insulin

          3. 5.2.1.1.3 Non-Insulin Injectable Drugs

          4. 5.2.1.1.4 Combination Drugs

          5. 5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

        2. 5.2.1.2 Mexico (Value and Volume 2012-2024)

          1. 5.2.1.2.1 Oral Anti-diabetic Drugs

          2. 5.2.1.2.2 Insulin

          3. 5.2.1.2.3 Non-Insulin Injectable Drugs

          4. 5.2.1.2.4 Combination Drugs

          5. 5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

        3. 5.2.1.3 Rest of Latin America (Value and Volume 2012-2024)

          1. 5.2.1.3.1 Oral Anti-diabetic Drugs

          2. 5.2.1.3.2 Insulin

          3. 5.2.1.3.3 Non-Insulin Injectable Drugs

          4. 5.2.1.3.4 Combination Drugs

          5. 5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes population (2012-2024)

    2. 6.2 Type-2 Diabetes population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Takeda

      2. 7.1.2 Pfizer

      3. 7.1.3 Eli Lilly

      4. 7.1.4 Janssen Pharmaceuticals

      5. 7.1.5 Astellas

      6. 7.1.6 Boehringer Ingelheim

      7. 7.1.7 Merck And Co.

      8. 7.1.8 AstraZeneca

      9. 7.1.9 Bristol Myers Squibb

      10. 7.1.10 Novartis

      11. 7.1.11 Sanofi

      12. 7.1.12 Novo Nordisk

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information